Annual Cash & Cash Equivalents
$275.14 M
-$203.61 M-42.53%
December 31, 2022
Summary
- As of February 10, 2025, IMGN annual cash & cash equivalents is $275.14 million, with the most recent change of -$203.61 million (-42.53%) on December 31, 2022.
- During the last 3 years, IMGN annual cash & cash equivalents has risen by +$98.91 million (+56.13%).
Performance
IMGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$605.53 M
+$33.55 M+5.87%
September 30, 2023
Summary
- As of February 10, 2025, IMGN quarterly cash and cash equivalents is $605.53 million, with the most recent change of +$33.55 million (+5.87%) on September 30, 2023.
- Over the past year, IMGN quarterly cash and cash equivalents has increased by +$296.02 million (+95.64%).
Performance
IMGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IMGN Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -42.5% | +95.6% |
| 3 y3 years | +56.1% | +221.7% |
| 5 y5 years | +3.0% | +99.7% |
IMGN Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.5% | at low | at high | -66.8% |
| 5 y | 5-year | -42.5% | -36.0% | at high | -70.9% |
| alltime | all time | -42.5% | -99.5% | at high | -99.9% |
ImmunoGen Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $605.53 M(+5.9%) |
| Jun 2023 | - | $571.99 M(+184.2%) |
| Mar 2023 | - | $201.25 M(-26.9%) |
| Dec 2022 | $275.14 M(-42.5%) | $275.14 M(-11.1%) |
| Sep 2022 | - | $309.51 M(-17.2%) |
| Jun 2022 | - | $373.87 M(-14.6%) |
| Mar 2022 | - | $437.66 M(-8.6%) |
| Dec 2021 | $478.75 M(+62.9%) | $478.75 M(+94.8%) |
| Sep 2021 | - | $245.76 M(+2.6%) |
| Jun 2021 | - | $239.54 M(-15.4%) |
| Mar 2021 | - | $283.12 M(-3.7%) |
| Dec 2020 | $293.86 M(+66.8%) | $293.86 M(+56.1%) |
| Sep 2020 | - | $188.22 M(-14.3%) |
| Jun 2020 | - | $219.51 M(-11.2%) |
| Mar 2020 | - | $247.30 M(+40.3%) |
| Dec 2019 | $176.22 M(-32.8%) | $176.22 M(-13.8%) |
| Sep 2019 | - | $204.49 M(-14.7%) |
| Jun 2019 | - | $239.82 M(-11.3%) |
| Mar 2019 | - | $270.40 M(+3.1%) |
| Dec 2018 | $262.25 M(-1.8%) | $262.25 M(-13.5%) |
| Sep 2018 | - | $303.20 M(-12.1%) |
| Jun 2018 | - | $345.06 M(+58.0%) |
| Mar 2018 | - | $218.38 M(-18.2%) |
| Dec 2017 | $267.11 M(+67.0%) | $267.11 M(+37.1%) |
| Sep 2017 | - | $194.85 M(+29.6%) |
| Jun 2017 | - | $150.34 M(+18.8%) |
| Mar 2017 | - | $126.57 M(-35.4%) |
| Dec 2016 | $159.96 M(-34.7%) | - |
| Sep 2016 | - | $196.00 M(-20.0%) |
| Jun 2016 | $245.03 M(-11.9%) | $245.03 M(+34.0%) |
| Mar 2016 | - | $182.91 M(-13.8%) |
| Dec 2015 | - | $212.28 M(-14.3%) |
| Sep 2015 | - | $247.84 M(-10.9%) |
| Jun 2015 | $278.11 M(+95.5%) | $278.11 M(+148.7%) |
| Mar 2015 | - | $111.83 M(+4.9%) |
| Dec 2014 | - | $106.60 M(-12.5%) |
| Sep 2014 | - | $121.80 M(-14.4%) |
| Jun 2014 | $142.26 M(-27.0%) | $142.26 M(-13.3%) |
| Mar 2014 | - | $164.08 M(-7.9%) |
| Dec 2013 | - | $178.09 M(+1.9%) |
| Sep 2013 | - | $174.84 M(-10.3%) |
| Jun 2013 | $194.96 M(+21.1%) | $194.96 M(-5.4%) |
| Mar 2013 | - | $206.10 M(-2.3%) |
| Dec 2012 | - | $211.02 M(-9.7%) |
| Sep 2012 | - | $233.61 M(+45.2%) |
| Jun 2012 | $160.94 M(-15.8%) | $160.94 M(-8.2%) |
| Mar 2012 | - | $175.26 M(+4.1%) |
| Dec 2011 | - | $168.37 M(-6.3%) |
| Sep 2011 | - | $179.76 M(-6.0%) |
| Jun 2011 | $191.21 M(+75.2%) | $191.21 M(+65.1%) |
| Mar 2011 | - | $115.81 M(-9.9%) |
| Dec 2010 | - | $128.49 M(+35.3%) |
| Sep 2010 | - | $94.94 M(-13.0%) |
| Jun 2010 | $109.16 M(+56.7%) | $109.16 M(+166.0%) |
| Mar 2010 | - | $41.03 M(-19.9%) |
| Dec 2009 | - | $51.22 M(-12.7%) |
| Sep 2009 | - | $58.64 M(-15.8%) |
| Jun 2009 | $69.64 M(+120.2%) | $69.64 M(+88.9%) |
| Mar 2009 | - | $36.86 M(-1.5%) |
| Dec 2008 | - | $37.43 M(+19.9%) |
| Sep 2008 | - | $31.21 M(-1.3%) |
| Jun 2008 | $31.62 M(+198.2%) | $31.62 M(+104.4%) |
| Mar 2008 | - | $15.47 M(+25.1%) |
| Dec 2007 | - | $12.37 M(-52.9%) |
| Sep 2007 | - | $26.27 M(+147.8%) |
| Jun 2007 | $10.61 M | $10.61 M(+44.7%) |
| Mar 2007 | - | $7.33 M(+41.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | - | $5.18 M(-17.4%) |
| Sep 2006 | - | $6.28 M(+30.4%) |
| Jun 2006 | $4.81 M(+40.6%) | $4.81 M(+18.8%) |
| Mar 2006 | - | $4.05 M(-39.4%) |
| Dec 2005 | - | $6.69 M(+168.3%) |
| Sep 2005 | - | $2.49 M(-27.2%) |
| Jun 2005 | $3.42 M(-49.4%) | $3.42 M(-55.5%) |
| Mar 2005 | - | $7.70 M(+11.1%) |
| Dec 2004 | - | $6.93 M(-0.2%) |
| Sep 2004 | - | $6.94 M(+2.6%) |
| Jun 2004 | $6.77 M(-33.2%) | $6.77 M(-65.9%) |
| Mar 2004 | - | $19.85 M(+108.2%) |
| Dec 2003 | - | $9.53 M(+74.9%) |
| Sep 2003 | - | $5.45 M(-46.2%) |
| Jun 2003 | $10.13 M(-37.6%) | $10.13 M(+36.3%) |
| Mar 2003 | - | $7.43 M(-17.3%) |
| Dec 2002 | - | $8.99 M(-41.0%) |
| Sep 2002 | - | $15.24 M(-6.1%) |
| Jun 2002 | $16.23 M(+9.5%) | $16.23 M(-19.2%) |
| Mar 2002 | - | $20.08 M(+45.1%) |
| Dec 2001 | - | $13.84 M(-17.1%) |
| Sep 2001 | - | $16.70 M(+12.7%) |
| Jun 2001 | $14.82 M(+952.1%) | $14.82 M(-11.9%) |
| Mar 2001 | - | $16.83 M(-88.2%) |
| Dec 2000 | - | $142.15 M(+630.6%) |
| Sep 2000 | - | $19.46 M(+1281.1%) |
| Jun 2000 | $1.41 M(-66.5%) | $1.41 M(-33.8%) |
| Mar 2000 | - | $2.13 M(-56.6%) |
| Dec 1999 | - | $4.90 M(-12.5%) |
| Sep 1999 | - | $5.60 M(+33.3%) |
| Jun 1999 | $4.20 M(+147.1%) | $4.20 M(+50.0%) |
| Mar 1999 | - | $2.80 M(+40.0%) |
| Dec 1998 | - | $2.00 M(-16.7%) |
| Sep 1998 | - | $2.40 M(+41.2%) |
| Jun 1998 | $1.70 M(0.0%) | $1.70 M(-26.1%) |
| Mar 1998 | - | $2.30 M(-14.8%) |
| Dec 1997 | - | $2.70 M(+42.1%) |
| Sep 1997 | - | $1.90 M(+11.8%) |
| Jun 1997 | $1.70 M(-39.3%) | $1.70 M(-32.0%) |
| Mar 1997 | - | $2.50 M(+38.9%) |
| Dec 1996 | - | $1.80 M(+80.0%) |
| Sep 1996 | - | $1.00 M(-64.3%) |
| Jun 1996 | $2.80 M(-6.7%) | $2.80 M(+12.0%) |
| Mar 1996 | - | $2.50 M(+177.8%) |
| Dec 1995 | - | $900.00 K(-70.0%) |
| Sep 1995 | - | $3.00 M(0.0%) |
| Jun 1995 | $3.00 M(+87.5%) | $3.00 M(-50.8%) |
| Mar 1995 | - | $6.10 M(+916.7%) |
| Sep 1994 | - | $600.00 K(-62.5%) |
| Jun 1994 | $1.60 M(-83.2%) | $1.60 M(-70.4%) |
| Mar 1994 | - | $5.40 M(+350.0%) |
| Dec 1993 | - | $1.20 M(-81.3%) |
| Sep 1993 | - | $6.40 M(-32.6%) |
| Jun 1993 | $9.50 M(-75.0%) | $9.50 M(+2.2%) |
| Mar 1993 | - | $9.30 M(-57.9%) |
| Dec 1992 | - | $22.10 M(-48.0%) |
| Sep 1992 | - | $42.50 M(+11.8%) |
| Jun 1992 | $38.00 M(+137.5%) | $38.00 M(+14.8%) |
| Mar 1992 | - | $33.10 M(+50.5%) |
| Sep 1991 | - | $22.00 M(+37.5%) |
| Jun 1991 | $16.00 M(+81.8%) | $16.00 M(-57.9%) |
| Mar 1991 | - | $38.00 M(+617.0%) |
| Dec 1990 | - | $5.30 M(-36.9%) |
| Sep 1990 | - | $8.40 M(-4.5%) |
| Jun 1990 | $8.80 M(+22.2%) | $8.80 M(-37.1%) |
| Mar 1990 | - | $14.00 M(+145.6%) |
| Sep 1989 | - | $5.70 M(-20.8%) |
| Jun 1989 | $7.20 M | $7.20 M |
FAQ
- What is ImmunoGen annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ImmunoGen?
- What is ImmunoGen annual cash & cash equivalents year-on-year change?
- What is ImmunoGen quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ImmunoGen?
- What is ImmunoGen quarterly cash and cash equivalents year-on-year change?
What is ImmunoGen annual cash & cash equivalents?
The current annual cash & cash equivalents of IMGN is $275.14 M
What is the all time high annual cash & cash equivalents for ImmunoGen?
ImmunoGen all-time high annual cash & cash equivalents is $478.75 M
What is ImmunoGen annual cash & cash equivalents year-on-year change?
Over the past year, IMGN annual cash & cash equivalents has changed by -$203.61 M (-42.53%)
What is ImmunoGen quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IMGN is $605.53 M
What is the all time high quarterly cash and cash equivalents for ImmunoGen?
ImmunoGen all-time high quarterly cash and cash equivalents is $605.53 M
What is ImmunoGen quarterly cash and cash equivalents year-on-year change?
Over the past year, IMGN quarterly cash and cash equivalents has changed by +$296.02 M (+95.64%)